$122 Million is the total value of Knoll Capital Management, LLC's 30 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 68.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $55,746,000 | -10.2% | 857,494 | 0.0% | 45.68% | +27.5% | |
| APLT | Buy | Applied Therapeutics Inc | $15,258,000 | -33.6% | 734,980 | +13.0% | 12.50% | -5.8% |
| CRBP | Corbus Pharmaceuticals HLDGS | $9,083,000 | -78.5% | 5,045,870 | 0.0% | 7.44% | -69.5% | |
| ORGS | Orgenesis, Inc. | $6,634,000 | -17.1% | 1,316,364 | 0.0% | 5.44% | +17.7% | |
| EIGR | Buy | Eiger Biopharmaceuticals Inc | $4,845,000 | -4.3% | 595,238 | +13.3% | 3.97% | +35.8% |
| ALDX | Aldeyra Therapeutics Inc | $4,219,000 | +77.7% | 569,405 | 0.0% | 3.46% | +152.2% | |
| ABEO | Abeona Therapeutics Inc | $2,917,000 | -64.2% | 2,859,767 | 0.0% | 2.39% | -49.2% | |
| AVXL | Sell | Anavex Life Sciences Corp | $2,825,000 | -22.0% | 620,789 | -14.3% | 2.32% | +10.8% |
| XCUR | Exicure Inc | $2,236,000 | -27.1% | 1,277,777 | 0.0% | 1.83% | +3.4% | |
| LUMN | Lumen Technologies Inc | $2,220,000 | +2.3% | 220,000 | 0.0% | 1.82% | +45.2% | |
| ENTX | Entera Bio Ltd | $2,159,000 | -28.3% | 1,741,363 | 0.0% | 1.77% | +1.7% | |
| BX | Blackstone Group LP | $2,088,000 | -7.0% | 40,000 | 0.0% | 1.71% | +31.9% | |
| DOW | Dow Inc | $1,416,000 | +15.8% | 30,000 | 0.0% | 1.16% | +64.3% | |
| SNGX | Soligenix Inc. | $1,410,000 | -11.0% | 787,830 | 0.0% | 1.16% | +26.4% | |
| MTEM | Molecular Templates | $1,244,000 | -19.2% | 113,905 | 0.0% | 1.02% | +14.6% | |
| BTAI | BioXCel Therapeutics Inc | $867,000 | -19.0% | 20,000 | 0.0% | 0.71% | +14.9% | |
| CTVA | Corteva Inc | $864,000 | +6.5% | 30,000 | 0.0% | 0.71% | +51.3% | |
| DD | Dupont de Nemours Inc | $832,000 | +6.0% | 15,000 | 0.0% | 0.68% | +50.6% | |
| SA | New | SEABRIDGE GOLD INC | $601,000 | – | 32,000 | +100.0% | 0.49% | – |
| MMX | New | MAVERIX METALS INC | $591,000 | – | 115,000 | +100.0% | 0.48% | – |
| AEM | New | AGNICO EAGLE MINES LTD | $549,000 | – | 6,900 | +100.0% | 0.45% | – |
| EQX | New | EQUINOX GOLD CORP | $533,000 | – | 45,500 | +100.0% | 0.44% | – |
| KL | New | KIRKLAND LAKE GOLD LTD | $524,000 | – | 10,750 | +100.0% | 0.43% | – |
| FNV | New | FRANCO NEV CORP | $523,000 | – | 3,750 | +100.0% | 0.43% | – |
| OR | New | OSISKO GOLD ROYALTIES LTD | $496,000 | – | 190,000 | +100.0% | 0.41% | – |
| MAG | New | MAG SILVER CORP | $281,000 | – | 17,300 | +100.0% | 0.23% | – |
| FSM | New | FORTUNA SILVER MINES INC | $278,000 | – | 43,700 | +100.0% | 0.23% | – |
| SILV | New | SILVERCREST METALS INC | $263,000 | – | 31,000 | +100.0% | 0.22% | – |
| SVM | New | SILVERCORP METALS INC | $264,000 | – | 36,500 | +100.0% | 0.22% | – |
| PAAS | New | PAN AMERN SILVER CORP | $264,000 | – | 8,200 | +100.0% | 0.22% | – |
| CATS | Exit | Catasys Inc | $0 | – | -43,034 | -100.0% | -0.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.